Higher radiation dose on immune cells is associated with radiation-induced lymphopenia and worse prognosis in patients with locally advanced esophageal squamous cell carcinoma

被引:3
|
作者
Qiu, Jianjian [1 ]
Lin, Hancui [1 ]
Ke, Dongmei [1 ]
Yu, Yilin [1 ]
Xu, Jiaying [1 ]
Qiu, Hejin [1 ]
Zheng, Qunhao [1 ]
Li, Hui [1 ]
Zheng, Hongying [1 ]
Liu, Lingyun [1 ]
Wang, Zhiping [1 ]
Yao, Qiwei [1 ]
Li, Jiancheng [1 ]
机构
[1] Fujian Med Univ, Fujian Canc Hosp, Clin Oncol Sch, Fuzhou, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2023年 / 14卷
关键词
effective dose to immune cells (EDIC); esophageal carcinoma; radiation-induced lymphopenia (RIL); prognosis; radiotherapy; LYMPHOCYTE NADIR; OPEN-LABEL; CANCER; SURVIVAL; CHEMORADIATION; RADIOTHERAPY; NIVOLUMAB; IMPACT; PEMBROLIZUMAB; MULTICENTER;
D O I
10.3389/fimmu.2023.1066255
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
BackgroundTo explore the effective dose to immune cells (EDIC) for better prognosis while avoiding radiation-induced lymphopenia (RIL) in patients with locally advanced esophageal squamous cell carcinoma (ESCC). Materials and methodsOverall, 381 patients with locally advanced ESCC receiving definitive radiotherapy with or without chemotherapy (dRT +/- CT) between 2014 and 2020 were included in this study. The EDIC model was calculated by radiation fraction number and mean doses to the heart, lung, and integral body. The correlation between EDIC and clinical outcomes was analyzed using Cox proportional hazards regression, and risk factors for RIL were determined by logistic regression analysis. ResultsThe median EDIC was 4.38 Gy. Multivariate analysis revealed that low-EDIC significantly improved the OS of patients when compared with high-EDIC (HR = 1.614, P = 0.003) and PFS (HR = 1.401, P = 0.022). Moreover, high-EDIC was associated with a higher incidence of grade 4 RIL (OR = 2.053, P = 0.007) than low-EDIC. In addition, we identified body mass index (BMI), tumor thickness, and nodal stage as independent prognostic factors of OS and PFS, while BMI (OR = 0.576, P = 0.046) and weight loss (OR = 2.214, P = 0.005) as independent risk factors of grade 4 RIL. In subgroup analyses, the good group had better clinical outcomes than the remaining two groups (P< 0.001). ConclusionThis study demonstrated that EDIC significantly correlates with poor clinical outcomes and severe RIL. Optimizing treatment plans to decrease the radiation doses to immune cells is critical for improving the outcomes.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Influence of Neoadjuvant Radiation Dose on Patients Undergoing Esophagectomy and Survival in Locally Advanced Esophageal Cancer
    Ising, Mickey S.
    Marino, Katy
    Trivedi, Jaimin R.
    Rojan, Adam A.
    Dunlap, Neal E.
    van Berkel, Victor
    Fox, Matthew P.
    JOURNAL OF GASTROINTESTINAL SURGERY, 2019, 23 (04) : 670 - 678
  • [42] Radiation-induced hypothyroidism in patients of oral squamous cell carcinoma: A retrospective analysis of 195 patients
    Jain, Prateek, V
    Das, Avipsa
    Manikantan, Kapila
    Sharan, Rajeev
    Mallick, Indranil
    Chatterjee, Sanjoy
    Arun, Pattatheyil
    INDIAN JOURNAL OF CANCER, 2022, 59 (04) : 480 - 484
  • [43] PD1+ tumor associated macrophages predict poor prognosis of locally advanced esophageal squamous cell carcinoma
    Lu, Yufei
    Guo, Leiming
    Ding, Gaofeng
    FUTURE ONCOLOGY, 2019, 15 (35) : 4019 - 4030
  • [44] Prognostic Effect of the Dose of Radiation Therapy and Extent of Lymphadenectomy in Patients Receiving Neoadjuvant Chemoradiotherapy for Esophageal Squamous Carcinoma
    Pai, Chu-Pin
    Chien, Ling-, I
    Huang, Chien-Sheng
    Hsu, Han-Shui
    Hsu, Po-Kuei
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (17)
  • [45] Systemic Inflammation Score for Predicting Radiation-Induced Trismus and Osteoradionecrosis of the Jaw Rates in Locally Advanced Nasopharyngeal Carcinoma Patients
    Somay, Efsun
    Sezen, Duygu
    Selek, Ugur
    Besen, Ali Ayberk
    Mertsoylu, Huseyin
    Topkan, Erkan
    UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, 2023, 33 (03): : 158 - 169
  • [46] Neoadjuvant vs definitive concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma patients
    Chen, Chih-Yi
    Li, Chia-Chin
    Chien, Chun-Ru
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2018, 16
  • [47] Endoscopic traversability in patients with locally advanced esophageal squamous cell carcinoma: Is it a significant prognostic factor?
    Shin, Hae Jin
    Moon, Hee Seok
    Kang, Sun Hyung
    Sung, Jae Kyu
    Jeong, Hyun Yong
    Kim, Seok Hyun
    Lee, Byung Seok
    Kim, Ju Seok
    Yun, Gee Young
    MEDICINE, 2017, 96 (51)
  • [48] A phase I dose escalation study of Nimotuzumab in combination with concurrent chemoradiation for patients with locally advanced squamous cell carcinoma of esophagus
    Zhao, Kuai-le
    Hu, Xi-chun
    Wu, Xiang-hua
    Fu, Xiao-long
    Fan, Min
    Jiang, Guo-Liang
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (04) : 1585 - 1590
  • [49] APOC1 predicts a worse prognosis for esophageal squamous cell carcinoma and is associated with tumor immune infiltration during tumorigenesis
    Cao, Xiying
    Wu, Bingqun
    Guo, Shaoming
    Zhong, Weixiang
    Zhu, Shenyu
    Zhang, Zuxiong
    Gu, Liang
    Li, Hui
    PATHOLOGY & ONCOLOGY RESEARCH, 2023, 29
  • [50] Prediction of prognosis after trimodal therapy in patients with locally advanced squamous cell carcinoma of the oesophagus
    Stahl, Michael
    Lehmann, Nils
    Walz, Martin K.
    Stuschke, Martin
    Wilke, Hansjochen
    EUROPEAN JOURNAL OF CANCER, 2012, 48 (16) : 2977 - 2982